{
    "name": "amivantamab",
    "comment": "Rx",
    "other_names": [
        "Rybrevant",
        "amivantamab-vmjw"
    ],
    "classes": [
        "MET Tyrosine Kinase Inhibitors",
        "Antineoplastics",
        "EGFR Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/rybrevant-amivantamab-4000216",
    "pregnancy": {
        "common": [
            "Based on mechanism of actions and findings in animal models, fetal harm may occur when administered to pregnant females",
            "No data are available on use in pregnant females or animal data to assess drug risk in pregnancy",
            "Verify pregnancy status of females of reproductive potential before initiating therapy"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "No animal studies conducted",
                    "Disruption or depletion of EGFR in animal models resulted in impairment of embryofetal development (eg, effects on placental, lung, cardiac, skin, neural development)",
                    "Absence of EGFR or MET signaling has resulted in embryolethality, malformations, and postnatal death in animals",
                    "Human IgG1 is known to cross the placenta; therefore, amivantamab has potential to be transmitted from mother to developing fetus"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 3 months after final dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on drug presence in human milk or on milk production, or its effects on breastfed children",
            "Advise females not to breastfeed during treatment and for 3 months after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "ILD/pneumonitis reported; monitor for new or worsening symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever)",
                "May cause ocular toxicity (eg, keratitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, uveitis); promptly refer patients with eye symptoms to an ophthalmologist",
                "Based on mechanism of action and findings from animal models, fetal harm may occur when administered to pregnant females"
            ],
            "specific": [
                {
                    "type": "IRRs",
                    "description": [
                        "IRRs occurred",
                        "Signs and symptoms of IRRs include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting",
                        "Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse as recommended",
                        "Monitor any signs and symptoms of infusion reactions during infusion in a setting where cardiopulmonary resuscitation medication and equipment are available"
                    ]
                },
                {
                    "type": "Dermatologic adverse reactions",
                    "description": [
                        "TEN, rash (including dermatitis acneiform), pruritus, and dry skin reported",
                        "Instruct patient to limit sun exposure during and for 2 months after treatment ",
                        "Advise patients to wear protective clothing and use broad-spectrum UVA/UVB sunscreen",
                        "For dry skin, recommend alcohol-free emollient cream",
                        "If skin reactions develop, start topical corticosteroids and topical and/or oral antibiotics",
                        "For Grade 3 reactions, add oral steroids and consider dermatologist consultation",
                        "Promptly refer to a dermatologist if patients do not improve within 2 weeks or present with severe rash or atypical appearance or distribution"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Rash",
            "percent": "84"
        },
        {
            "name": "Decrease albumin",
            "percent": "79"
        },
        {
            "name": "Infusion",
            "percent": "64"
        },
        {
            "name": "related reaction",
            "percent": "56"
        },
        {
            "name": "Increased glucose",
            "percent": "53"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "50"
        },
        {
            "name": "Paronychia",
            "percent": "47"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "46"
        },
        {
            "name": "Increased creatinine",
            "percent": "38"
        },
        {
            "name": "Increased ALT",
            "percent": "37"
        },
        {
            "name": "Dyspnea",
            "percent": "36"
        },
        {
            "name": "Nausea",
            "percent": "36"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "33"
        },
        {
            "name": "Decreased phosphate",
            "percent": "33"
        },
        {
            "name": "Increased AST",
            "percent": "27"
        },
        {
            "name": "Decreased magnesium",
            "percent": "27"
        },
        {
            "name": "Increased gamma",
            "percent": "27"
        },
        {
            "name": "glutamyl transferase",
            "percent": "26"
        },
        {
            "name": "GGT",
            "percent": "26"
        },
        {
            "name": "Decreased sodium",
            "percent": "33"
        },
        {
            "name": "Decreased potassium",
            "percent": "27"
        },
        {
            "name": "Stomatitis",
            "percent": "25"
        },
        {
            "name": "Fatigue",
            "percent": "23"
        },
        {
            "name": "Edema",
            "percent": "22"
        },
        {
            "name": "Cough",
            "percent": "19"
        },
        {
            "name": "Constipation",
            "percent": "18"
        },
        {
            "name": "Vomiting",
            "percent": "16"
        },
        {
            "name": "Hemorrhage",
            "percent": "15"
        },
        {
            "name": "Pruritus",
            "percent": "14"
        },
        {
            "name": "Diarrhea",
            "percent": "13"
        },
        {
            "name": "Decreased appetite",
            "percent": "13"
        },
        {
            "name": "Dry skin",
            "percent": "12"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "11"
        },
        {
            "name": "Pyrexia",
            "percent": "10"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        },
        {
            "name": "Abdominal pain",
            "percent": "8"
        },
        {
            "name": "Pneumonia",
            "percent": "8"
        },
        {
            "name": "Headache",
            "percent": "8"
        },
        {
            "name": "Decreased albumin",
            "percent": "6"
        },
        {
            "name": "Decreased phosphate",
            "percent": "4.8"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "4"
        },
        {
            "name": "Decreased potassium",
            "percent": "4"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "4"
        },
        {
            "name": "Increased glucose",
            "percent": "3.9"
        },
        {
            "name": "Increased GGT",
            "percent": "3.1"
        },
        {
            "name": "Decreased sodium",
            "percent": "3.1"
        },
        {
            "name": "Rash",
            "percent": "3.1"
        },
        {
            "name": "Diarrhea",
            "percent": "2.3"
        },
        {
            "name": "Paronychia",
            "percent": "2.3"
        },
        {
            "name": "Infusion related reaction",
            "percent": "1.6"
        },
        {
            "name": "Dyspnea",
            "percent": "0.8"
        },
        {
            "name": "Fatigue",
            "percent": "0.8"
        },
        {
            "name": "Increased ALT",
            "percent": "0.8"
        },
        {
            "name": "Abdominal pain",
            "percent": "0.8"
        },
        {
            "name": "Dizziness",
            "percent": "0.8"
        },
        {
            "name": "Headache",
            "percent": "0.8"
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        }
    ]
}